Trulieve Cannabis Corp. Subordi
TRLV
Positions held
Your positionsTRLV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Trulieve Cannabis Corp. is strategically positioned in the growing cannabis industry, which is expected to expand as more states legalize cannabis for medical and recreational use.
- The company's gross margin improved to 59.9% in the latest quarter, up from 59.3% in the prior quarter.
- Trulieve's current ratio stands at 5.942, indicating strong liquidity and the ability to cover short-term obligations.
- Despite the positive gross margin, Trulieve has faced revenue declines, with a 6% decrease in revenue from the prior quarter, dropping to $271 million.
- The company reported a net income loss of $405.975 million in the latest quarter, reflecting ongoing profitability challenges.
- Trulieve's revenue growth has been negative at -10.3%, indicating difficulties in maintaining sales momentum.
Fundamentals
| Market cap | $2.00B | Enterprise value | $2.25B | Trailing P/E | — | Forward P/E | 18.63 |
| PEG | — | Price / book | 2.60 | Beta | 1.81 | Dividend yield | 0.00% |
| Revenue growth | -10.3% | Earnings growth | — | Gross margin | 59.5% | Operating margin | 12.8% |
| Profit margin | -41.6% | ROE | -47.7% | ROA | 3.3% | Debt / equity | 0.75 |
| Current ratio | 5.94 | Free cash flow | $232.04M | Analyst recommendation | strong_buy | Mean target | $18.18 |
| 52w high | $13.28 | 52w low | $4.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $271M | $287M | $293M | $288M | $302M | — |
| Op margin | 12.8% | 12.4% | 6.6% | 14.4% | 17.3% | — |
| Net income | -$406M | $2.4M | -$42.9M | -$26.8M | -$13.8M | — |
| Gross margin | 59.9% | 59.3% | 59.8% | 58.9% | 60.6% | — |
| Gross profit | $162M | $170M | $175M | $170M | $183M | — |
| Operating income | $34.8M | $35.4M | $19.4M | $41.4M | $52.4M | — |
- Revenue -6% vs prior quarter ($271M vs $287M).
- Gross margin 59.9% (was 59.3% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.2B | — |
| Op margin | 12.6% | 7.8% | 8.2% | 10.3% | — |
| Net income | -$116M | -$155M | -$527M | -$246M | — |
| Gross margin | 60.2% | 60.3% | 52.1% | 56.6% | — |
| Gross profit | $711M | $716M | $589M | $689M | — |
| Operating income | $148M | $92.5M | $92.6M | $126M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Trulieve Repays $65 Million Mortgage Strengthening Balance Sheet
2026-10-07 · Trulieve Repays $65 Million Mortgage Strengthening Balance Sheet
2026-10-06 · Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026
2026-10-06 · Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026
2026-10-03 · 2 High-Octane Cannabis Stocks to Buy in October for Aggressive Investors
2026-10-01 · Trulieve Cannabis (TRLV) Falls On Rescheduling Delay, Is It Now A Bargain?
2026-09-30 · Cannabis Investors Were Betting On Washington, Then Washington Hit Pause
2026-09-30 · Cannabis Stocks Are Slumping. A Procedural DEA Delay Is to Blame.
2026-09-30 · Trulieve Sinks 14% as DEA Judge Pauses Cannabis Rescheduling Over GAO Report Flagging “Gaps”
2026-09-30 · MSOS, TRLV Slide After Hours As DEA Judge Pauses Cannabis Rescheduling Case
2026-09-28 · Trulieve Secures Exclusive Alien Labs, Connected Licensing Rights in Florida, Texas
2026-09-28 · Trulieve Announces Exclusive Master Licensing Agreement with Connected for Florida and Texas
Price (daily)
Full chart · RSI · MACD · patterns